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ES-62 is a phosphorylcholine (PC)-containing glycoprotein secreted by the filarial nematode 
Acanthocheilonema viteae that acts to modulate the host immune response to promote the establishment of 
chronic helminth infection. Reflecting its anti-inflammatory actions, we have previously reported that ES-62 
protects mice from developing Collagen-Induced Arthritis (CIA): thus, as this helminth-derived product may 
exhibit therapeutic potential in Rheumatoid Arthritis (RA), it is important to understand the protective 
immunoregulatory mechanisms triggered by ES-62 in this model in vivo. We have established to date that ES-
62 acts by down-regulating pathogenic Th17/IL-17-mediated responses and up-regulating IL-10. In addition, 
our studies have identified that IL-22, another member of the IL-10 family of cytokines, exerts dual pathogenic 
and protective roles in this model of RA with ES-KDUQHVVLQJ WKHF\WRNLQH¶V LQIODPPDWLRQ-resolving and 
tissue repair properties in the joint during the established phase of disease. Here, we discuss the counter-
regulatory roles of IL-22 in the murine model of CIA and present additional novel data showing that ES-62 
selectively induces Ȗį T cells with the capacity to produce IL-22 and that Ȗį T cells with the capacity to produce 
IL-22, but not IL-17, induced during CIA can be identified by their expression of TLR4. Moreover, we also 
show that treatment of mice undergoing CIA with the active PC moiety of ES-62, in the form of PC conjugated 
to BSA, is not only sufficient to mimic the ES-62-dependent suppression of pathogenic IL-17 responses shown 
previously but also that of the IL-22 and IL-10 up-regulation observed with the parasitic worm product during 
CIA. These findings not only reinforce the potential of IL-22, firstly described as a Th17-related pro-
inflammatory cytokine, as a protective factor in arthritis but also suggest that drugs based on the PC moiety 
found in ES-62 may be able to harness the joint-protecting activities of IL-22 therapeutically. 
To cite this article: Margaret M. Harnett, et al. The parasitic worm product ES-62 up-regulates IL-22 production by Ȗį T 
cells in the murine model of Collagen-Induced Arthritis. Inflamm Cell Signal 2014; 1: e308. doi: 10.14800/ics.308. 
Copyright: © 2014 The Authors. Licensed under a Creative Commons Attribution 4.0 International License which allows 
users including authors of articles to copy and redistribute the material in any medium or format, in addition to remix, 
transform, and build upon the material for any purpose, even commercially, as long as the author and original source are 
properly cited or credited. 
 
Introduction 
ES-62 is a phosphorylcholine (PC)-containing 
glycoprotein secreted by the rodent filarial nematode 
Acanthocheilonema viteae and a homologue of excretory-
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secretory products that can be detected in the bloodstream 
of humans infected with Brugia malayi and Onchocerca 
volvulus [1]. Our early in vitro studies revealed that this 
parasite-derived molecule exhibits a broad range of 
immunomodulatory effects, for example the dampening of 
the pro-inflammatory responses of macrophages and 
dendritic cells[2, 3], that likely promote persistence of the 
parasite in the host without severely immunocompromising 
it. Although its mechanism of action is not yet fully 
understood, TLR4 is a major target of ES-62 [4] and most of 
its anti-inflammatory properties depend on its unusual post-
translational addition of PC: thus, when PC is chemically 
linked to an irrelevant protein such as BSA or ovalbumin, 
as with ES-62, it inhibits full activation of macrophages and 
DCs following TLR stimulation in a TLR4-dependent 
manner[5].  
In accordance with the Hygiene Hypothesis [6] that has 
led to the proposal that the recent dramatic increase in 
allergy and autoimmune diseases in industrialized countries 
is related to the eradication of parasitic infections, a wide 
range of studies have shown infection with helminths to be 
protective against such disorders in experimental models, 
suggesting that such parasites or their immunomodulatory 
products could be exploited therapeutically. Reflecting this, 
we have shown that treatment with ES-62, either 
prophylactically or therapeutically, reduces disease 
severity and incidence of Collagen-Induced Arthritis 
(CIA), a murine model of human Rheumatoid Arthritis 
(RA)[7] and PC-BSA is able to protect mice in a similar 
Figure 1. Kinetic analysis of IL-22-producing NK and ȖįT cells in DLN of mice 
with CIA. ES-62- and PBS-treated mice undergoing CIA were culled every 7 days (n=4 
for each treatment group at each time-point) and IL-22 expression by DLN cells 
analysed by intracellular flow cytometry. Proportions of spontaneously IL-22-producing, 
CD49b+ 1.7FHOOV$DQGȖį7&5+ T cells (B) from individual mice were evaluated as 
described in the Material and Methods. The proportions of IL-17-producing NK (C) and 
ȖįT cells (D) were also analysed at d28. Red symbols represent CIA mice treated with 
PBS whilst black symbols represent mice treated with ES-62. Values are the mean ± 
SEM of 4 individual mice at each time-point. *p<0.05, **p<0.01. 
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fashion to that of ES-62 [8, 9]. An increasing number of 
studies have shown that helminths and their secreted 
products exert their anti-inflammatory effects by actively 
modulating host immune effector mechanisms, for 
example, by reducing aberrant Th1 or Th2 responses and 
promoting IL-10-dependent regulatory pathways [10-12]. 
Indeed, some of these actions have been associated with the 
mechanism of action underlying ES-62-mediated 
protection in CIA. Thus, protection was first associated 
with suppressed Th1 responses, reduced levels of collagen-
specific IgG2a antibodies and increased IL-10 production 
[7, 13]
. However, ES-62 failed to protect against other Th1-
driven models of disease [14, 15], suggesting that alternative 
pathways might be targeted in CIA. Indeed, ES-62-
mediated protection was subsequently shown to be 
associated with down regulation of IL-17 production, a 
finding consistent with increasing evidence that this 
cytokine is a major pathogenic driver in RA as IL-17 
induces hyperplasia and proliferation of synoviocytes, 
production of pro-inflammatory mediators and promotion 
of TLR-dependent responses and recruitment of immune 
system cells including T cells, B cells and neutrophils [16-
18]
. Interestingly, ES-62 down-regulates IL-17 production 
by a multi-pronged mechanism, inhibiting Th17 
polarization both directly and indirectly, the latter via the 
suppression of IL-6 and IL-23 release by DCs, key 
cytokines in DC-priming of Th17 differentiation. ES-62 
also targets DCs to modulate the cross-WDONEHWZHHQȖį7
cells and DCs, resulting in reduced levels of IL-17 
production by the innate lymphocytes. Collectively, these 
actions result in down-regulated expression of IL-17 in the 
joints of mice with CIA and reduced synovial 
inflammation[19]. Importantly, as biologics targeting IL-17 
have resulted in some opportunistic fungal infections under 
clinical trial, IL-17-producing NK cells which have been 
shown to be protective in such infections remain unaffected 
in ES-62-treated mice undergoing CIA[20]. Thus ES-62 
attenuates IL-17-mediated responses without fully 
inhibiting them, as a result suppressing pathogenic, but not 
infection-combating sources of IL-17 and these findings 
may go some way to explaining why helminth infections or 
ES-62-based treatments do not substantially 
immunocompromise the host.  
More recently, we have investigated the effect of ES-62 
on another component of the IL-23/IL-17 inflammatory 
axis in autoimmune arthritis, namely IL-22 which had also 
been reported to be a pro-inflammatory cytokine in RA [21, 
22]
. Consistent with this, we showed that neutralisation of 
IL-22 prior to onset of disease blocks joint pathology. 
However, we have also shown that IL-22 is required for ES-
¶VDQWL-arthritic effects, via a mechanism in which IL-22-
signalling desensitizes synovial fibroblast (SF) responses to 
pro-inflammatory factors such as IL-17 in the joint [23]. As 
a result, SFs produce less IL-6 and the number of 
Figure 2. TLR4 expression by Ȗį7FHOOV LVDVVRFLDWHGZLWKWKHLUSURGXFWLRQRI ,/-22 in mice with Collagen-Induced Arthritis. 
Representative plots of the gating strategy for analysis of intracellular IL-17 and IL-H[SUHVVLRQE\Ȗį TCR+ and CD49b+ NK T cells in 
the DLN from a single CIA mouse following ex vivo stimulation with PMA/ionomycin are shown (A). Expression of TLR4 (tinted grey 
histograms) ZDVGHWHUPLQHGDFFRUGLQJWRDSSURSULDWHLVRW\SHFRQWUROVLQȖį T cells and CD49b+NK T cells respectively. Data represent 
Mean Fluorescence Intensity (MFI) ± SD of DLN cells (B) from 5 individual mice (***p<0.001) undergoing CIA from a single experiment 
representative of two independent experiments. 
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neutrophils infiltrating the joints is significantly reduced. 
These findings are consistent with increasing evidence 
suggesting that IL-22 can play dual pathogenic and, 
reflecting its wound healing properties [24], protective roles 
in RA. It is therefore essential to fully understand the role(s) 
of IL-22 in the pathogenesis of arthritis and the resolution 
of inflammation and protection against joint damage 
induced by the helminth product in order to translate these 
potentially therapeutic actions to the clinic. The aim of this 
report is therefore to provide further insight into the sources 
of IL-22 modulated by ES-62 in mice with CIA and in 
particular we show that a subset of Ȗį7FHOOVWKDWH[SUHVV
TLR4 in vivo is a major potential producer of such 
protective IL-22. In addition, we also report that PC-BSA 
mimics the ability of ES-62 to up-regulate IL-22 production 
during protection from CIA: thus as we have recently 
provided proof of principle that small drug-like PC-based 
compounds can be protective in mouse models of arthritis 
and asthma[9, 25], this latter finding highlights the novel 
potential of parasite-derived products to harness the 
therapeutic properties of IL-22 in RA.  
Material and Methods 
CIA. Animals were maintained in the Biological 
Services Units in accordance with the Home Office UK 
Licences PPL60/3580, PPL60/3119 and PIL60/12183 and 
the Ethics Review Boards of the Universities of Glasgow 
Figure 3. PC-BSA protection against CIA is associated with up-regulation of serum IL-
22 and IL-10. Mice undergoing CIA were treated with BSA (n=4) or PC-BSA (n=4). Arthritis 
scores (A) at day 32 after initial collagen injections are shown, expressed as mean scores ± 
SEM for BSA- or PC-BSA-treatment groups. Disease incidence is also shown (B), indicated 
by the % of mice develRSLQJDVHYHULW\VFRUH S. IL-22 (C&E) and IL-10 (D & F) 
levels were evaluated by ELISA in serum of naïve (n=3), BSA- (n=4) and PC-BSA-treated 
(n=4) individual mice and plotted as mean values of triplicate analyses (C & D). *p<0.05 and 
***p<0.001.The correlations between IL-22 (E; n = 8, r = 0.6726, p = 0.0127) and IL-10 (F; n 
= 8, r = 0.406, p = 0.088) serum concentrations for all mice undergoing CIA (BSA- and PC-
BSA-treated groups) and clinical scores are shown (E & F). 
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and Strathclyde. CIA was induced in male DBA/1 mice (8-
10 weeks old; Harlan Olac; Bicester, UK) by intradermal 
immunization with bovine type II collagen (CII, MD 
%LRVFLHQFHV LQ FRPSOHWH )UHXQG¶V DGMXYDQW )&$ DQG
mice were treated with purified endotoxin-free ES-62 from 
A. viteae or PC-BSA (2 µg/dose) or PBS subcutaneously on 
days -2, 0 and 21[7, 8]. Mice were monitored for clinical 
symptoms of arthritis: severity scores represent 0=normal; 
1=erythema; 2=erythema plus swelling; 3=extension of 
swelling; 4=loss of function, and the disease score is the 
sum for the four limbs.  
Ex vivo analysis. DLN cells (106/ml) were stimulated in 
the presence and absence of PMA (50 ng/ml) plus 
ionomycin (500 ng/ml) for 1 h before being incubated with 
ȝJPO%UHIHOGLQ$6LJPD-Aldrich, UK) for 5 h at 37oC 
with 5% CO2. Live cells were discriminated by the 
Figure 4. Protective effects of ES-62 observed in the CIA model. ES-62 targets a complex cell network to 
regulate cytokine production and effector responses in the joint of CIA mice. In serum, ES-62/PC-BSA up-
regulates IL-10 and IL-22, but strongly down-regulates IL-17 (1). In draining lymph nodes, IL-17 production by Ȗį
T cells and conventional CD4 T cells, is down-regulated by ES-62 via modulation of DC responses (2). This is 
reflected in vitro by ES-62 targeting DCs to down-regulate TLR-mediated production of IL-23, IL-6 and IL-1, 
resulting in reduced Th17 priming and inhibited induction of IL-17-SURGXFLQJȖį7FHOOV,QDGGLWLRQ(6-62 directly 
inhibits IL-1-dependent differentiation of Th17 in vitro by downregulation of MyD88 (3). Analysis of joint cells by 
flow cytometry and immunohistochemistry (4) revealed that at the site of inflammation, ES-62 down-regulates the 
levels of antibody producing B cells and restores the levels of IL-10 producing B cells. In addition, the IL-17/IL-
22 balance is reset with protective IL-22 responses desensitising synovial fibroblasts to IL-17, further suppressing 
IL-17-dependent inflammatory pathways, including the IL-6 production by synoviocytes and the subsequent 
recruitment of pro-inflammatory cells like neutrophils (5). Furthermore, the residual neutrophils infiltrating the joint 
exhibit a modulated phenotype and produce higher amounts of IL-22 (and lower levels of IL-,)1Ȗ and IL-6), 
to perpetuate the protective mechanisms of ES-62 in the joint. 
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LIVE/DEAD fixable aqua dye (BioLegend, UK) and 
phenotypic markers labelled using FITC-conjugated anti-
CD49b (BioLegend, UK), APC-conjugated anti-Ȗį TCR 
(eBioscience, UK) and biotin-conjugated anti-TLR4 
antibodies before the cells were fixed and permeabilized 
according to BioLegend protocols. Pacific Blue-conjugated 
streptavidin was used for detection of biotinylated 
antibodies. Cytokines were stained using PerCP-Cy5.5±
conjugated anti±IL-17A (BioLegend, UK) or PE-
conjugated anti±IL-22 antibodies (R&D Systems, UK) for 
30 minutes prior to analysis by flow cytometry, gating 
according to appropriate isotype controls[19, 23]. 
Cytokine analysis. Serum levels of IL-22 and IL-10 
were determined by ELISA, according to the 
manufacturers' recommendations (R&D Systems; 
Biolegend). 
Statistical analysis 'DWD ZHUH DQDO\]HG E\ 6WXGHQW¶V
unpaired 1-tailed t-test. Articular scores were analysed by 
the Mann-Whitney test. P values *<0.05 were considered 
significant. 
Results and Discussion 
ES-62 differentially regulates IL-22 production by Ȗį
and NK T cells in DLN from mice undergoing CIA. 
Protection by ES-62 in the CIA model has been associated 
with counter-regulation of IL-17 and IL-22 levels in serum 
and joints during the established phase of pathology, with 
exposure to the parasite product elevating IL-22 but 
reducing IL-17 levels [19, 23]. Similarly, exposure to ES-62 
reduces IL-17, but not IL-22 production by DLN and joint 
cells ex vivo and analysis revealed these cytokines to be 
predominantly produced by distinct populations of cells at 
both sites [19, 23]. Moreover, whilst ES-62 inhibited the 
levels of both spontaneous and PMA/ionomycin-stimulated 
IL-17 production by CD4+ DLN cells, it only reduced the 
proportion of unstimulated CD4+ DLN cells expressing IL-
22 [23]. However, although we have shown the parasite 
product to additionally suppress the levels of IL-17+ Ȗį T 
cells whilst leaving the levels of IL-17-producing NK cells 
unaffected [26], the effects of ES-62 on IL-22 production by 
these subsets of innate lymphocytes was not investigated. 
We therefore decided to evaluate this in order to potentially 
identify a source of protective IL-22 production in the DLN 
during CIA progression (Fig.1). Consistent with our 
previous observations that exposure to ES-62 appeared to 
have little effect on the levels of IL-22-producing DLN 
cells [23], whilst kinetic analysis suggested that the 
proportion of both NK and Ȗį7FHOOVH[SUHVVLQJ,/-22 was 
elevated in those DLN from ES-62 exposed mice 
undergoing CIA following challenge (day 21; Fig. 1A&B), 
this only reached significance for ȖįT cells (at d28; Fig. 
1B). By contrast, the proportion of ȖįIL-17+ but not NK 
IL-17+ T cells was reduced at this time point (Fig. 1C&D). 
These data suggest that ȖįT cells, which by bridging innate 
and adaptive immunity play important immunoregulatory 
roles in RA [27], are selectively targeted by ES-62 to 
modulate the IL-17/IL-22 balance in the CIA model to 
mediate its protective effects. Interestingly, this kinetic 
analysis also revealed, consistent with IL-22 playing a 
pathogenic role during the initiation phase of disease that 
the levels of IL-22-SURGXFLQJȖį7 cells in the DLN peaked 
within about 7 days and then generally declined with 
disease progression in PBS-treated mice undergoing CIA. 
By contrast, and supporting their proposed protective role, 
exposure to ES-62 helps maintain the levels of IL-22+ ȖįT 
cells at time points where pathology is normally established 
in the joint. Although we do not know whether these cells 
can migrate to the joint and hence are representative of the 
IL-22-expressing lymphocyte-like cells previously shown 
to be elevated in ES-62-treated mice at this stage [23], these 
results could suggest that the observed increase of IL-22 in 
serum and joints of ES-62-treated mice might be a result of 
Ȗį 7 FHOO PRGXODWLRQ UDWKHU WKDQ HIIHFWV RQ FRQYHQWLRQDO
Th22 cells and may correlate with a report that CD4+ T cells 
isolated from synovial samples from RA patients were not 
able to produce IL-22 [22].  
IL-22-SURGXFLQJȖį7FHOOVEXWQRW,/-17-producing 
Ȗį7FHOOVH[SUHVV7ROO-like receptor 4 (TLR4). It is not 
clear how ES-62 selectively targets JG but not NK T cells, 
to render them respectively sensitive or resistant to 
modulation of IL-17/IL-22 production as both these cell 
types express pattern recognition receptors (PRR) 
important in CIA pathogenesis [28], such as TLR2 [29] and 
ES-62 has been shown to subvert TLR signalling by down 
regulation of MyD88 in a variety of cell types [4, 19, 30-33]. 
However, TLR4 is required for ES-62 action and although 
this PRR is not generally considered to be expressed by 
either JG or NK T cells, TLR4+ Ȗį 7 FHOOV KDYH been 
described following burn injury [34] and we have recently 
reported that a population of these cells, but not NK T cells 
can be found in the DLN of mice undergoing CIA [20]. Thus, 
as TLR4 signalling has been reported to promote IL-17 
production in Ȗį T cells isolated from lungs and lymphoid 
organs [35], we hypothesised that differential expression of 
this PRR may be involved in the selective regulation of IL-
17/IL-SURGXFWLRQE\Ȗį7FHOOVDQG1.7FHOOV Ln the 
CIA model. Although analysis of DLN cells from mice 
with CIA confirmed that TLR4+ Ȗį7FHOOVGLGQRWH[SUHVV
IL-17 [20, 28], perhaps surprisingly, but consistent with our 
previous findings that IL-17 and IL-22 were predominantly 
expressed by distinct populations of DLN cells, we 
observed a positive correlation between IL-22 expression 
and TLR4 on JG, but not NK, T cells (Fig. 2A & B). This 
is the first observation of IL-22+TLR4+ Ȗį7FHOOVLQWKH&,$
model, and this subset may be analogous to the population 
of IL-22+IL-17- Ȗį 7 FHOOV WKDW KDV EHHQ VKRZQ WR EH
protective in models of colon inflammation [36] and lung 
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fibrosis [37]. A similar association between other cell 
VXUIDFH PDUNHUV DQG F\WRNLQH SURILOH H[SUHVVLRQ LQ Ȗį 7
cells has previously been reported in that IL-17+ Ȗį7FHOOV
DQG ,)1Ȗ+ Ȗį 7 FHOOV GLIIHUHQWLDOO\ H[SUHVV the markers 
CD25 and CD122 respectively [38, 39], suggesting that 
expression of particular cell sensors can dictate functional 
Ȗį7 cell responses and thus, phenotyping may allow the 
possibility of distinguishing potentially protective IL-22+ 
Ȗį7FHOOVIURPSDWKRJHQLF,/-17+ Ȗį7FHOOV:KHWKHU(6-
62 can induce "protective" IL-22+ Ȗį T cells via TLR4 
signalling and/or differentially and temporally modulate 
IL-17 and IL-22 production by distinct subsets of Ȗį T cells 
is currently under investigation in our laboratory. Thus, 
although whether ES-62 acts via TLR4 to modulate IL-22 
H[SUHVVLRQE\Ȗį7FHOOVGXULQJ&,$LVVWLOOXQFOHDULWLVDQ
attractive hypothesis in terms of allowing selective 
modulation of the immune response given that we have 
previously shown that ES-62-mediated down regulation of 
IL-17 production by Ȗį T cells reflects inhibition of their 
activation by DCs [23] and that NK T cells, which do not 
express TLR4, are not affected by ES-62 in terms of either 
IL-17 or IL-22 production[20] (Fig. 1).  
Phosphorylcholine (PC) mimics the ability of ES-62 
to increase IL-22 levels in the bloodstream of CIA 
animals. Collectively, our data indicate that ES-62 can 
selectively modify critical regulatory IL-17/IL-22 
pathways in the CIA model. Of note, therapies based on its 
mode of action promoting resetting of the protective: 
pathogenic T cell effector balance of this inflammatory axis 
that focus on the differential suppression of IL-17/IL-22-
producing innate cell populations are perhaps less likely to 
leave the host open to opportunistic fungal infections, than 
current strategies involving novel biological agents like 
monoclonal IL-17 neutralizing antibodies. This new 
generation of immunomodulators is in phase II clinical 
trials (secukinomab [40], ixekizumab [41] and brodalumab 
[42]), but already it seems clear that more studies are needed 
to establish their long-term safety as some reports showed 
increased rates of such infection concomitant with 
treatment [43-45]. ES-62 thus presents certain advantages as 
a potential anti-arthritic treatment: reduced risk of 
immunosuppression since IL-17-driven responses are 
limited but not abrogated, regulation of a complex network 
of cells rather than a key regulatory molecule and the 
additional ability to trigger damage repair mechanisms, 
such as IL-22-mediated pathways of inflammation 
resolution and wound healing. However, as a large 
potentially immunogenic protein, ES-62 still presents 
important limitations preventing its translation into the 
clinic. Nevertheless, new ES-62-based interventional 
approaches can still be developed as the bioactive PC 
moiety, when conjugated to an "inert" carrier protein such 
as BSA, can also protect mice against CIA (Fig. 3A-B). 
Indeed, studies involving PC-BSA were the starting point 
for our development of small molecular analogues (SMAs) 
that mimic the anti-inflammatory ability of ES-62 in 
targeting pathogenic IL-17 responses in mouse models of 
arthritis and asthma[9, 25] and provide proof of concept for 
helminth-based drugs in inflammatory disease. 
Although protection by PC-BSA against CIA also 
reflects down-regulation of pathogenic IL-17-dependent 
responses[9], our earlier studies suggested that PC does not 
necessarily reproduce all of the potentially protective 
effects of ES-62. For example, whilst PC conjugated to 
ovalbumin (PC-OVA) also ameliorated joint pathology in 
CIA models, it did not reduce the levels of potentially 
pathogenic anti-collagen IgG2a antibodies that are 
additionally decreased in ES-62-treated mice [8]. Therefore, 
we decided to investigate whether PC-BSA-mediated 
protection against CIA also reflected the up-regulation of 
IL-22 required for protection by ES-62 [23]. Interestingly 
therefore, whilst as we have shown previously, CIA mice 
presented elevated levels of IL-22 in serum compared to 
naïve mice [23], it was found that such PC-BSA-treated mice 
exhibit significantly higher levels of IL-22 (3.5-fold 
increase, Fig.3C) and these serum levels of IL-22 inversely 
correlate with the clinical scores of the mice with CIA (Fig. 
3E).Taken together, these findings corroborate our 
previous results observed with ES-62 and further support 
our hypothesis that the high levels of IL-22 observed in the 
serum of such mice during established disease, reflect the 
ability of this cytokine to resolve inflammation and joint 
damage properties of this cytokine in the CIA model[23]. 
Increased levels of IL-22 are also associated with 
elevated levels of IL-10 in serum obtained from PC-
BSA-treated CIA mice. We have previously shown that 
protection against CIA in mice afforded by ES-62 is 
associated not only with inflammation-resolving IL-22 
responses, but also with elevated splenic IL-10 production 
[7] which may reflect restoration of the levels of B cells with 
potential (IL-10-dependent) regulatory capacity [13]. 
Interestingly, therefore, a recent study has suggested that 
IL-22-mediated amelioration of CIA severity is associated 
with increased levels of IL-10[46]. Moreover, IL-22 has also 
recently been reported to suppress experimental 
autoimmune uveitis via generation of IL-10-producing 
regulatory CD11b+antigen presenting cells [47]. Therefore, 
we decided to evaluate the levels of IL-10 in serum of PC-
BSA-treated mice, to determine whether there was 
concomitant up-regulation of IL-22 and IL-10 levels, as 
observed with ES-62. Indeed, treatment with PC-BSA 
was found to restore the levels of serum IL-10 which had 
tended to be down-regulated in CIA mice to those observed 
in naive mice (Fig. 3D): moreover, and consistent with a 
protective role for this cytokine, such IL-10 levels also 
inversely correlated with CIA articular disease scores (Fig. 
3F). These results suggest that PC-BSA is able to reproduce 
the ability of ES-62 to promote IL-10 production in the CIA 
Inflammation & Cell Signaling 2014; 1: e308. doi: 10.14800/ics.308; © 2014 by Margaret M. Harnett, et al. 
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model[8]: although the cell type responsible for such IL-10 
production is still unknown, it is possible that PC-BSA 
promotes IL-10-producing regulatory B cells, rather than 
regulatory T cells, as with ES-62 in CIA mice [13]. 
Mechanistically, since neutralizing anti-IL-10 antibodies 
were shown to abrogate the protective effect of IL-22 in 
CIA [46], such restoration of IL-10 levels by PC-BSA might 
impact on DC-dependent priming of Th17 and IL-17-
producing ȖįT cells, consistent with the reduced levels of 
IL-17 observed in serum of PC-BSA-treated CIA mice [9]. 
Thus understanding the mechanisms responsible for 
controlling cytokine networks such as those resulting in the 
ES-62-mediated counter-regulation of IL-10/IL-22/IL-17 
responses (Summarized in Fig. 4), rather than the analysis 
of the individual cytokines, may clarify the contradictory 
data relating to, for example, whether IL-22 is a pro- or 
anti-inflammatory mediator in RA.  
Concluding Remarks 
IL-22 was originally described as a pro-inflammatory 
mediator in RA. This reflects findings that mice deficient 
in this cytokine were resistant to developing CIA[48] as well 
as reports that IL-22 levels and Th22 cells are elevated in 
the serum of RA patients [21] and also that IL-22 has been 
shown to induce proliferation of human SF and promote 
RANKL production and osteoclastogenesis in vitro[49]. 
However, whilst IL-22 levels are up-regulated in RA 
patients and IL-22 has been shown to be involved in bone 
damage and RANKL production, certain studies report that 
such IL-22 up regulation does not contribute to the 
induction of synovial inflammation [21, 49-51]. Moreover, 
supporting our proposal of dual pathogenic and protective 
roles for IL-22 in RA based on the protective action of ES-
62 in CIA [23], recent studies have also shown that IL-22 
can play protective roles in CIA, via enhancing IL-10-
mediated immunoregulation [46] and, as with ES-62, 
desensitizing SFs to IL-17 [52]. Collectively, these data 
suggest that the precise role of IL-22 in RA - protective 
versus pathogenic -probably depends on the inflammatory 
context. This is likely to especially be the case with respect 
to its differential effects on SFs, which in RA are subject to 
a complex pro-inflammatory cocktail involving cytokines, 
chemokines and alarmins generated by the hypoxic 
conditions pertaining in the arthritic joint. These results 
therefore question the hypothesis that serum IL-22 levels 
provide a pathogenic biomarker in established RA and may 
even suggest that IL-22 is up-regulated in a homeostatic 
mechanism to limit and resolve joint inflammation and 
promote tissue repair. In any case, they dictate that 
therapies targeting IL-22 should be reconsidered while the 
role of the cytokine in the initiation and progression of 
synovial inflammation in RA awaits full understanding.  
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